IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials
Immune Network · 2024 · 24 (1)
DOI: 10.4110/in.2024.24.e2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immune Network, 2024. Verfasst von Choong-Hyun Koh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Seoul National University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea.
- Division of Life Sciences, College of Life Science and Bioengineering, Incheon National University, Incheon 22012, Korea.
- Research & Development Center, Cellid Co., Ltd., Seoul 08826, Korea.
- Laboratory of Cell & Gene Therapy, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea.
ORCID-Profile: Choong-Hyun Koh, Byung-Seok Kim, Chang-Yuil Kang, Yeonseok Chung, Hyungseok Seo
Förderung
- National Research Foundation of Korea
- Seoul National University
Zitieren
APA
Koh, C. H., Kim, B. S., Kang, C. Y., Chung, Y., & Seo, H. (2024). IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials. Immune Network, 24(1). https://doi.org/10.4110/in.2024.24.e2
Vancouver
Koh CH, Kim BS, Kang CY, Chung Y, Seo H. IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials. Immune Network. 2024;24(1). doi:10.4110/in.2024.24.e2
BibTeX
@article{Koh2024,
author = {Koh, Choong-Hyun and Kim, Byung-Seok and Kang, Chang-Yuil and Chung, Yeonseok and Seo, Hyungseok},
title = {IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials},
journal = {Immune Network},
year = {2024},
volume = {24},
number = {1},
doi = {10.4110/in.2024.24.e2}
}
EUVIMED